MedTrace Logo

Study to Assess CMR316 in Healthy Volunteers and Patients With Idiopathic Pulmonary Fibrosis

NCT06589219 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2025-04-23

No results posted yet for this study

Summary

The purpose of this study is to assess the safety, tolerability and pharmacokinetics single and multiple inhaled doses of CMR316 in healthy volunteers and patients with Idiopathic Pulmonary Fibrosis (IPF).

Conditions

  • Pulmonary Fibroses, Idiopathic

Interventions

DRUG

CMR316

CMR316 administered via nebulization at single or multiple dose(s) assigned by cohort

DRUG

Placebo

Placebo administered via nebulization at single or multiple dose(s) to match CMR316 administration

Sponsors & Collaborators

  • Calibr, a division of Scripps Research

    lead OTHER

Principal Investigators

  • Chan Beals, MD, PhD · Calibr-Skaggs Institute for Innovative Medicines

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-08-19
Primary Completion
2026-03-31
Completion
2026-03-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06589219 on ClinicalTrials.gov